You are here

CELDARA MEDICAL, LLC

Company Information
Address
16 CAVENDISH CT
LEBANON, NH 03766-1441
United States


http://www.celdaramedical.com

Information

UEI: MMVKQXZUBMQ7

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR Success: Celdara Medical LLC

    How much good could you do with $30 billion dollars and the smartest people in the world? That is the question that the founders of Celdara Medical asked themselves when beginning the company in 2008.Each year, the National Institutes of Health allocates $30 billion to the best and brightest...

Award Charts




Award Listing

  1. Cellular Immunotherapy for SSc

    Amount: $225,000.00

    Project Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Complex Dimensional in Vitro Human Skin Tissue Models for Scleroderma

    Amount: $225,000.00

    Abstract Project Summary Scleroderma Systemic Sclerosis SSc is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction fibrosis and inflammation One in three pa ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  3. IGF OT IGF MULTIPLEXED BIOMARKER ASSAY FOR CLASSIFICATION OF PATIENTS WITH SYSTEMIC SCLEROSIS

    Amount: $1,499,989.00

    Not Available

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  4. Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL

    Amount: $299,052.00

    DESCRIPTION provided by applicant The long term aim of this project is to advance BILT for clinical approval which will provide clinicians with a powerful addition to the armamentarium for treatin ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  5. Therapy of transplantation-induced oxidative injury using polymeric antioxidants

    Amount: $1,478,801.00

    DESCRIPTION provided by applicant Ischemia reperfusion I R injury during renal transplantation surgery is responsible for oxidative stresses which result in immune activation and graft rejection ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  6. Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF

    Amount: $224,944.00

    DESCRIPTION provided by applicant Idiopathic pulmonary fibrosis IPF kills about persons in the United States each year There are currently around Americans afflicted with this fat ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  7. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    Amount: $451,598.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-r ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  8. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    Amount: $224,985.00

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current imp ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  9. Therapy of transplantation-induced oxidative injury using polymeric antioxidants

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Ischemia-reperfusion (I/R) injury during renal transplantation surgery is responsible for oxidative stresses which result in immune activation and graft rejection. ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  10. PHASE I, SBIR CONTRACT, N43TR-14-001,?MUTIPLEXED BIOMARKER ASSAY FOR CLASSIFICATION OF PATIENTS?.

    Amount: $223,419.00

    Not Available

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government